Proscia today unveiled study results on a new artificial intelligence (AI) that predicts diagnostic agreement for melanoma. The findings highlight the potential of the technology to improve diagnostic accuracy for melanoma and other diseases with low pathologist concordance.
DeepDx® Prostate is a clinically validated and CEmarked AI-based image analysis algorithm for prostate core needle biopsy analysis that detects cancer and grades its severity according to the Gleason scoring system. DeepDx® Prostate is designed to alleviate the shortage of pathologists and their heavy workload, while reducing diagnostic subjectivity and variability. The DeepDx® Prostate algorithm analyses whole slide images of H&E stained biopsy specimens and provides color visualization and gland-level segmentation based on Gleason patterns. In addition, it supplies the proportion of each Gleason pattern among the three patterns, and automatically provides measurements of the total tissue and tumor lengths. The latest validation study of the DeepDx® algorithm demonstrated at 99% sensitivity and 97% specificity. Moreover, the algorithm has successfully analyzed more than 700,000 tissues cores between 2019 and 2021.
Deep Bio: Enhanced security and reliability through adherence to the globally recognized information security standardsSEOUL, SOUTH KOREA (PRWEB) OCTOBER 27, 2022Deep Bio, a pioneer in medical AI for digital pathology and cancer diagnostics support software, announced that it has acquired ISO/IEC 27001:2013 certification, the international information security management system standards.ISO/IEC 27001:2013 specifies the requirements for establishing, implementing, maintaining, and improving an information security management system and provides a risk management process so that organizations can accordingly keep their information safe. As the most widely-recognized certification for information security management, it strictly evaluates 144 criteria in 14 categories such as information security policy, security processes, security controls and services. By obtaining the certification, Deep Bio has demonstrated its commitment to protecting data through a systematic management for information security.“As we handle a myriad of medical data which require a more secure approach, we are very aware of the importance of information security above all else, and make every effort to build a thorough security management system,” said Sun Woo Kim, the CEO of Deep Bio. “Achieving the certification proves our robust data security management systems. We will keep renewing this certification so that our partners and customers can use our AI-based cancer diagnostic support software with confidence,” he mentioned.Deep Bio, which initiated AI-based pathology image analysis and cancer diagnosis research in Korea, is leading the digital transformation in pathology with Korea’s first approved AI-based cancer diagnostic support software DeepDx®-Prostate and AI-based prostate cancer severity-grading software DeepDx®-Prostate Pro. More importantly, the company plans to execute purchase agreements with five Korean hospitals for DeepDx®-Prostate Pro, through the Public Procurement Marketplace program run by the Korean Public Procurement Service (PPS).Deep Bio also continues to build its global presence through overseas partnerships with digital pathology platform providers in the US, Europe, and India, as well as conduct research cooperation with Stanford Medical School, Harvard Dana-Farber Cancer Institute, and other top research institutions in the US. The company also has been presenting its novel research results in prestigious science and technology journals including the Cancers Journal, npj Digital Medicine, among others.About Deep BioDeep Bio Inc. is an AI healthcare company with in-house expertise in deep learning and cancer pathology. Our vision is to radically improve efficiency and accuracy of pathologic cancer diagnosis and prognosis, by equipping pathologists with deep learning-based IVD SaMDs (In Vitro Diagnostics Software as a Medical Device), for optimal cancer treatment decisions. To learn more, visit http://www.deepbio.co.kr.DeepDx® Prostate is a clinically-validated AI for prostate core needle biopsy tissue image analysis. Whole-slide images (WSIs) of H&E-stained biopsy tissue specimens are analyzed for prostate cancer, Gleason scores and grade groups. Extensively tested at 4 US CLIA labs (700k+ cores from 2019 to 2021), DeepDx® Prostate can alleviate the shortage of pathologists and the resultant increase in workload, while reducing diagnostic subjectivity and variability. To learn more, visit http://www.deepbio.co.krSOURCE: CISION PR Web
Pramana, Inc., an AI-enabled health tech company modernizing the pathology sector, today announced a multi-year agreement with Caris Life Sciences (Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI. As part of the agreement, Pramana will digitize approximately 1.5 million slides per year with its family of intelligent scanning systems and advanced software, bringing efficiency to digital operations.
Cranfield, UK, 25th October 2022 – After announcing a sold-out exhibition and attendee register, Pathology Visions 2022 was certainly not one to be missed. The halls of the MGM Grand buzzed with vendor and pathologist enthusiasm, speaking volumes to the significance of digital pathology following a notable rise in interest during the COVID-19 pandemic. After speaking to many vendors at the show and attending multiple conference sessions, we share our thoughts below on what the conference’s discourse revealed about digital pathology’s immediate future.
EIZO, the Japanese specialist in image reproduction solutions, announces the launch of a new 24.1" colour monitor. The RadiForce MX243W is a widescreen monitor and factory calibrated with a DICOM® -GSDF luminance characteristic.
In this 1-hour webinar, learn about the AI-powered Slide QC 2.0 network that was recently released in HALO AI 3.5 for automatically detecting and reporting artifacts in both research and clinical workflows. The Slide QC network can segment artifacts including tissue folds, air bubbles, out-of-focus regions, dust and pen marks. Learn how the network was developed and how it performs against external test sets. Furthermore, learn how to use it and how to add your own training regions to improve artifact detection in your individual workflows. By attending this webinar, you will also learn how you can deploy it in a clinical environment with HALO AP to improve lab efficiency. The Slide QC network can be used in a clinical environment both to flag slides with a high percentage of artifacts for review and to identify artifacts and exclude them from downstream image analysis.
This episode’s guest, Andrew Janowczyk, is a computer scientist who has been active in the field of digital pathology since 2008. Before turning to the field of digital pathology he worked across the globe and across industries.
Digital pathology has matured. Is your lab maturing with It? The case for a modernized digital pathology platform
Advancing Digital Pathology with Automation Caris Life Sciences and Pramana have partnered to enhance digital pathology automation using Pramana’s Spectral HT scanning system. This advanced system improves efficiency by automatically detecting image errors, reducing barcode failures, and uniquely scanning double-thick slides, a feature not found in other scanners. High-Volume Digital Pathology Operations Caris Life Sciences processes [...]
